Cellexus Limited Appoints Discovery Scientific as Distributor in Canada
News Apr 08, 2010
Cellexus Limited, a supplier of single use, disposable bioreactors which are designed to simplify and improve cell culture and fermentation bioprocesses, has appointed Discovery Scientific as their distributor in Canada. This further distributor appointment is part of an ongoing geographical expansion to drive sales of the Cellexus products in key territories as the Company continues to grow.
Mr. Paul Stubbings, Cellexus Limited Chief Operating Officer, said in a statement, "Discovery Scientific is well established in the Canadian market with excellent contacts with customers in the market sectors for the Cellexus products. We are delighted to have entered into this distribution agreement which is illustrative of our ongoing commitment to broaden our geographical coverage with key distributors who are highly experienced in these markets. Selling into Canada presents unique challenges so it makes good business sense for us to work with Discovery Scientific, with the local knowledge and expertise as well as an established client base, to drive sales in this geography”.
Dr Martin Peet, CEO of Discovery Scientific commented "We are very pleased to be working with Cellexus Limited in the sales of the Cellexus single use, disposable bioreactor systems in Canada."
Dr Peet added: “Our strategy is to work with manufacturers with advanced R&D programs focused on improving current products or developing novel instrumentation to meet existing or emerging customer needs. Cellexus, with its ongoing development of single-use bioreactor systems, is totally aligned to this and we are looking forward to working with Cellexus to build sales in Canada”
The Cellexus CellMaker systems apply single-use, disposable cell culture bioreactor bags with efficient methods to mix and oxygenate. Whilst other systems require shakers, rockers, rollers or large environmental chambers, the CellMaker systems employ a novel airlift technology which is simple, scalable, inexpensive to use and proven to out-perform cell culture in flasks.
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE